Your institution may have access to this item. Find your institution then sign in to continue.
Title
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Authors
Kirkwood, J M; Strawderman, M H; Ernstoff, M S; Smith, T J; Borden, E C; Blum, R H
Abstract
Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma.
Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Vol 14, Issue 1, p7